Scholar Rock, A Top 10% Stock, Dives After Catalent Issues Hamper SMA Drug

Scholar Rock (SRRK) shares declined over 4% after the FDA rejected its spinal muscular atrophy drug, apitegromab, citing manufacturing concerns at a Catalent fill-finish facility now owned by Novo Nordisk. This regulatory setback is projected to delay the drug's launch by approximately four quarters, introducing near-term balance sheet risk. However, analysts largely maintain a positive long-term outlook, viewing the delay as temporary and highlighting apitegromab's unique mechanism, strong market positioning with limited competition, and potential for significant future sales despite revised price targets.

Analysis

Scholar Rock (SRRK) shares experienced a significant pullback, declining over 4% to $31.23, after the FDA issued a rejection for its spinal muscular atrophy (SMA) drug, apitegromab. The rejection is not based on the drug's clinical profile but stems from manufacturing deficiencies identified at a Catalent fill-finish facility, now owned by Novo Nordisk. This is a critical distinction, suggesting the core asset's viability remains intact. Analysts project this setback will delay the commercial launch by approximately four quarters, introducing near-term balance sheet risk and prompting a price target reduction from Wedbush to $43 from $50. Despite the delay, the long-term outlook remains positive among analysts, who reiterated outperform ratings. This optimism is supported by apitegromab's unique myostatin-blocking mechanism and its strong competitive positioning, particularly after the failure of Biohaven's rival drug, Talfa. The revised sales forecast, starting with just $7.9 million in 2026 but ramping to $511 million by 2028, quantifies the delayed but still substantial revenue potential.

Key Decisions for Investors

• Investors could view the share price decline as a strategic buying opportunity, as the regulatory setback is tied to a solvable, third-party manufacturing issue rather than a fundamental flaw in the drug's efficacy or safety.
• It is crucial to monitor Scholar Rock's cash burn and balance sheet over the next year, as the launch delay introduces financial risk that may necessitate a dilutive capital raise before revenue generation begins.
• The primary focus should be on tracking updates regarding the resolution of the Catalent facility's issues and the company's new timeline for resubmission to the FDA, as these will serve as key de-risking events and potential catalysts for the stock.